Sterling Deeside Limited

Active07235280 Private limited company

Incorporated: 26 April 2010 (16 years)
Previously known as: Adc Biotechnology Limited (until 3 April 2021)
Reaxa Biotech Ltd (until 18 May 2010)
This list may be incomplete. See all names on Companies House
Industry: Manufacture of pharmaceutical preparations (21200)
Directors: Septima Maguire
Karl Rotthier
Owned by: Sterling Pharma Solutions Limited
Accounts type: Audit exemption subsidiary
Region: Wales
Address: Unit 103 Tenth Avenue
Deeside Industrial Park
Deeside
CH5 2UA

Website & contact details

Group website: sterlingpharmasolutions.com via Sterling Pharma Solutions Limited
The site of this company’s group or brand.

Filing status

Accounts due: 31 March 2027
Last accounts: 31 March 2025
Conf. stmt due: 17 November 2027
Last conf. stmt: 3 November 2026

Charges

Total: 5
Outstanding: 1
Part satisfied: 0
Satisfied: 4

Officers 2 active

Officer details are public data from the Companies House register.

Maguire, Septima

Director · Appointed 5 May 2026

Also at Bibby Line Group Limited, Sterling Pharma Solutions Limited, Saffron Bidco Limited · more companies

Irish

Born May 1977 (49)

Rotthier, Karl

Director · Appointed 3 November 2025

Belgian

Born May 1967 (59)

Officer history (18 former)

5 May 2026

Appointed Maguire, Septima as Director

5 May 2026

Resigned Anderson, Matthew David as Director

3 November 2025

Appointed Rotthier, Karl as Director

31 October 2025

Resigned Cook, Kevin Peter as Director

22 November 2024

Appointed Anderson, Matthew David as Director

21 November 2024

Resigned Bahadur, Tushar Jain as Director

1 June 2021

Resigned Raymond, Alan Michael, Dr as Director

31 March 2021

Resigned Goward, Melanie Elizabeth Anne, Dr as Director

31 March 2021

Resigned Davies, John William as Director

31 March 2021

Resigned Rennison, Anita Isabella as Secretary

30 November 2020

Appointed Cook, Kevin Peter as Director

30 November 2020

Resigned Saxby, Simon James Yvon as Director

30 November 2020

Appointed Bahadur, Tushar Jain as Director

11 November 2020

Appointed Rennison, Anita Isabella as Secretary

11 November 2020

Resigned Rodriguez, James as Secretary

31 July 2020

Resigned Johnson, Charles Ian Robert as Director

29 January 2020

Appointed Rodriguez, James as Secretary

21 July 2019

Resigned Ferguson, John Alasdair Kerr Jamie, Dr as Director

22 February 2019

Resigned Banks, Russell Anthony as Director

22 February 2019

Resigned Banks, Russell Anthony as Secretary

30 April 2018

Appointed Saxby, Simon James Yvon as Director

17 April 2018

Resigned Evans, David John, Dr as Director

23 November 2017

Appointed Ferguson, John Alasdair Kerr Jamie, Dr as Director

23 November 2017

Appointed Banks, Russell Anthony as Director

29 September 2017

Appointed Banks, Russell Anthony as Secretary

29 September 2017

Appointed Goward, Melanie Elizabeth Anne, Dr as Director

29 September 2017

Resigned Collins, Christopher Castiel as Secretary

29 September 2017

Appointed Davies, John William as Director

16 May 2017

Resigned Jackson, Peter, Dr as Director

17 February 2017

Appointed Raymond, Alan Michael, Dr as Director

25 January 2016

Appointed Collins, Christopher Castiel as Secretary

25 January 2016

Resigned Thorn, Simon William as Secretary

10 January 2011

Resigned Jones, Howard Lee as Director

10 January 2011

Appointed Jackson, Peter, Dr as Director

14 September 2010

Appointed Johnson, Charles Ian Robert as Director

14 September 2010

Appointed Jones, Howard Lee as Director

26 April 2010

Appointed Thorn, Simon William as Secretary

26 April 2010

Appointed Evans, David John, Dr as Director

Ownership 1 active

People and entities with significant control, from the Companies House PSC register

Sterling Pharma Solutions Limited

Corporate entity · Notified 30 November 2020

Owns 75–100% of shares

Holds 75–100% of voting rights

Right to appoint and remove directors

Private Company Limited By Shares

Reg. no. 05712796

Former controllers (1)

30 November 2020

Ceased DBW Holdings Limited — Owns 25–50% of shares

Filings

Recent filings only. See the full history on Companies House

Date	Description	Made Up To
3 November 2026	Confirmation statement with updates	3 November 2026
6 June 2026	Confirmation statement with updates	31 May 2026
7 May 2026	Termination of appointment of a director
7 May 2026	Appointment of a director
20 April 2026	Statement of capital following an allotment of shares